<h1>Alivus Life Sciences Announces 15th AGM and Recommends Final Dividend of Rs 5.00 Per Share</h1>
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, has scheduled its Fifteenth (15th) Annual General Meeting (AGM). The company also announced the Board’s recommendation for a final dividend to be approved by shareholders at the upcoming meeting.
The 15th AGM is slated to be held on Tuesday, September 8, 2026. The gathering will utilize Video Conferencing (VC) or Other Audio-Visual Means (OAVM). Shareholders are advised of the key dates related to the dividend recommendation.
At its Board meeting conducted on May 14, 2026, the Directors recommended a final dividend amounting to Rs. 5.00 per Equity share. This decision was made considering the current face value of the company’s shares at Rs. 2 each for the financial year ending March 31, 2026.
To determine entitlement to this dividend, Alivus Life Sciences has set September 1, 2026, as the official Record Date. If the recommended dividend is approved during the AGM, payment is projected to be made on or after Friday, September 11, 2026.
The company detailed the distribution methods for the dividend:
- Beneficial Owners holding shares in dematerialized form will receive the dividend based on data held by the National Securities Depository Limited and Central Depository Services (India) Limited as of the close of business on September 1, 2026.
- Members holding shares in physical form must ensure valid transmission or transposition requests are lodged with Alivus by the close of business on September 1, 2026.
Key details regarding the dividend and AGM are summarized below:
| Event | Date/Details | Financial Figure |
|---|---|---|
| AGM Date | Tuesday, September 8, 2026 | N/A |
| Record Date | Tuesday, September 1, 2026 | N/A |
| Recommended Dividend (per share) | N/A | Rs. 5.00 |
| Face Value of Share | N/A | Rs. 2 each |
| Projected Payment Date | On or after September 11, 2026 | Subject to approval and TDS |
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.